Beta-Blockers for Heart Failure

Evidence-Based Alternatives with Proven Mortality Reduction

• The European Society of Cardiology recommends metoprolol succinate extended-release, with a starting dose of 12.5-25 mg once daily, titrated every 2 weeks to a target dose of 200 mg once daily, for patients with heart failure with reduced ejection fraction (HFrEF), due to its proven mortality benefit, with a 34% relative risk reduction in all-cause mortality in the MERIT-HF trial 1, 2, 3, 4
• The American Heart Association suggests bisoprolol, with a starting dose of 1.25 mg once daily, titrated every 2-4 weeks to a target dose of 10 mg once daily, for patients with HFrEF, due to its proven mortality benefit, with a 34% relative risk reduction in the CIBIS-II trial 1, 2, 4

Critical Pharmacologic Differences

• The European Society of Cardiology notes that carvedilol is not interchangeable with other beta-blockers, such as metoprolol succinate and bisoprolol, due to its unique properties, including alpha-1, beta-1, and beta-2 receptor blockade, providing additional vasodilation through alpha-blockade 1, 3
• The American College of Cardiology states that metoprolol succinate and bisoprolol are selective beta-1 blockers only, lacking alpha-blockade and vasodilatory effects, and should not be used as substitutes for carvedilol without careful consideration of their pharmacologic differences 1, 4

Dosing Equivalency Considerations

• The European Society of Cardiology recommends that when switching from carvedilol CR to metoprolol succinate or bisoprolol, the dose should be started low and titrated every 2 weeks, due to the lack of direct mathematical conversion ratio between these agents, and the different pharmacologic properties of each medication 4, 5

Clinical Decision Algorithm

• The American Heart Association suggests choosing metoprolol succinate extended-release if the patient prefers once-daily dosing similar to Coreg CR, or if the patient has symptomatic hypotension on carvedilol, due to its less pronounced alpha-blockade 4
• The European Society of Cardiology recommends choosing bisoprolol if the patient needs most consistent beta-1 blockade, or if the patient has renal impairment, due to its dual hepatic/renal elimination 4, 6